Brentuximab Vedotin

Antibody–drug conjugate

Approvedregulatory verdict

Evidence outlook

Approved: Diffuse Large B-Cell Lymphoma, Large B-Cell Lymphoma, Peripheral T-Cell Lymphoma, Cutaneous T-Cell Lymphoma, High-Grade B-Cell Lymphoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 2

Also approved (7)
US
  • ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine; pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide; adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation; adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates; adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone; adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen; adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy; adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product.
    Outside this platform's coverageFDA label
  • Relapsed Classical Hodgkin Lymphoma (cHL) ADCETRIS is indicated for the treatment of adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.
    FDA label
  • Previously Untreated Systemic Anaplastic Large Cell Lymphoma (sALCL) or Other CD30-Expressing Peripheral T-cell Lymphomas (PTCL), in Combination with Chemotherapy ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone.
    FDA label
  • Relapsed Systemic Anaplastic Large Cell Lymphoma (sALCL) ADCETRIS is indicated for the treatment of adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.Outside this platform's coverageFDA label
  • Relapsed Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) or CD30-Expressing Mycosis Fungoides (MF) ADCETRIS is indicated for the treatment of adult patients with pcALCL or CD30-expressing MF who have received prior systemic therapy.
    Outside this platform's coverageFDA label
Product first approved 2011
JP
  • Treatment of relapsed or refractory CD30- positive Hodgkin’s lymphoma and anaplastic large- cell lymphoma
Product first approved 2014PMDA
EU
  • Hodgkin lymphomaAdcetris is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).Adcetris is indicated for adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD).Adcetris is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).Adcetris is...
Product first approved 2012Outside this platform's coverageEMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (15)
Cutaneous T-Cell Lymphoma
NCT07178457 · Assistance Publique - Hôpitaux de Paris
2025-11-01 – 2032-11-01 · Cutaneous T Cell Lymphoma (CTCL), Brentuximab Vedotin
What this study did
Diffuse Large B-Cell Lymphoma
NCT06186986 · University Medical Center Groningen
2024-01 – 2026-01 · Diffuse Large B-cell-lymphoma
What this study did
Peripheral T-Cell Lymphoma
NCT07258680 · N.N. Petrov National Medical Research Center of Oncology
2013-10 – 2028-12 · Peripheral T-cell Lymphoma
What this study did
Other / comorbidity
NCT04685616 · University College, London
2022-04-14 – 2032-09 · Hodgkin Lymphoma
What this study did
NCT05675410 · National Cancer Institute (NCI)
2023-05-11 – 2031-04-28 · Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
What this study did
NCT05711628 · National Cancer Institute (NCI)
2023-08-10 – 2028-06-30 · Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
What this study did
NCT02166463 · National Cancer Institute (NCI)
2015-03-19 – 2027-10-14 · Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Childhood Hodgkin Lymphoma, Classic Hodgkin Lymphoma
What this study did
NCT03907488 · National Cancer Institute (NCI)
2019-08-29 – 2027-03-28 · Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
What this study did
NCT01712490 · Takeda
2012-11-09 – 2026-02-02 · Hodgkin Lymphoma
What this study did
NCT02661503 · University of Cologne
2016-07 – 2025-09 · Classical Hodgkin Lymphoma
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT06563245 · Children's Cancer Group, China
2024-09-25 – 2039-11-15 · Classical Hodgkin Lymphoma, Child, Adolescent, Young Adult, Metabolic Response, Survival, Treatment, Brentuximab Vedotin, PET Scan
What this study did
NCT07572123 · National Cancer Institute (NCI)
2026-12-04 – 2029-03-31 · Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
What this study did
NCT05595447 · Hospital Regional de Alta Especialidad del Bajio
2022-10-18 – 2025-10-18 · Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
What this study did
Phase 2 (92)
Cutaneous T-Cell Lymphoma
NCT07717580 · Peking University First Hospital
2026-07-31 – 2028-12-30 · Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Primary Cutaneous Anaplastic Large Cell Lymphoma
What this study did
NCT01352520 · M.D. Anderson Cancer Center
2011-06 – 2028-01-31 · CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Lymphomatoid Papulosis, Mycosis Fungoides, Skin Lymphoma, Cutaneous Lymphomas, Lymphoma, Hematologic Disorder
What this study did
NCT03587844 · Memorial Sloan Kettering Cancer Center
2018-07-03 – 2027-07 · Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
What this study did
NCT05357794 · M.D. Anderson Cancer Center
2022-10-13 – 2027-01-30 · Mycosis Fungoides
What this study did
NCT01396070 · Youn Kim
2011-05 – 2016-05 · Non-Hodgkin Lymphoma (NHL), Cutaneous Lymphoma, Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome
What this study did
Diffuse Large B-Cell Lymphoma
NCT06925555 · The First Affiliated Hospital with Nanjing Medical University
2025-09 – 2028-12-30 · EBV-Positive Diffuse Large B-Cell Lymphoma, Nos, Brentuximab Vedotin
What this study did
NCT02734771 · Patrick Reagan
2016-06 – 2025-12 · Diffuse Large B-Cell Lymphoma
What this study did
NCT02594163 · Seagen Inc.
2015-10 – 2017-09 · Diffuse Large B-cell Lymphoma Refractory, Follicular B-cell Non-Hodgkin's Lymphoma
What this study did
NCT02623920 · University of Arizona
2015-12-16 – 2017-05-17 · Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, Grey Zone Lymphoma, High Grade B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
What this study did
NCT01925612 · Seagen Inc.
2013-08 – 2017-05-01 · Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse
What this study did
Large B-Cell Lymphoma
NCT04745949 · M.D. Anderson Cancer Center
2021-05-10 – 2027-08-03 · Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma
What this study did
NCT02423291 · Fondazione Italiana Linfomi - ETS
2013-10 – 2016-07 · Primary Mediastinal Large B Cell Lymphoma
What this study did
Non-Small Cell Lung Cancer
Peripheral T-Cell Lymphoma
NCT04795869 · Northwestern University
2020-03-01 – 2029-03 · Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
What this study did
NCT03113500 · City of Hope Medical Center
2017-12-04 – 2027-04-25 · Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Angioimmunoblastic T-Cell Lymphoma, Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
What this study did
NCT04569032 · Seagen, a wholly owned subsidiary of Pfizer
2020-11-12 – 2026-01-12 · Peripheral T-cell Lymphoma
What this study did
NCT01716806 · Seagen Inc.
2012-10-31 – 2023-09-12 · Hodgkin Disease, Peripheral T Cell Lymphoma
What this study did
NCT03947255 · Seagen Inc.
2019-10-28 – 2022-11-06 · Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma
What this study did
NCT03496779 · The Lymphoma Academic Research Organisation
2018-04-10 – 2022-10-08 · Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
What this study did
Other / comorbidity
NCT07002216 · University of Miami
2025-07-15 – 2030-07-15 · Hodgkin Lymphoma, Advanced Hodgkin Lymphoma
What this study did
NCT07013565 · New York Medical College
2025-08-07 – 2030-07-01 · Anaplastic Large Cell Lymphoma, ALK-Positive
What this study did
NCT07275216 · City of Hope Medical Center
2027-01-01 – 2029-10-20 · Classic Hodgkin Lymphoma
What this study did
NCT05039073 · Emory University
2022-05-02 – 2028-11-30 · Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
What this study did
NCT01703949 · University of Washington
2013-03-20 – 2028-08-16 · Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
What this study did
NCT05313243 · Yale University
2023-07-10 – 2028-07-30 · T-Cell Lymphoma
What this study did
NCT03755804 · St. Jude Children's Research Hospital
2018-12-12 – 2028-07-01 · Hodgkin Lymphoma
What this study did
NCT04587687 · University of California, Davis
2020-12-04 – 2028-05 · Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
What this study did
NCT01920932 · St. Jude Children's Research Hospital
2013-08-12 – 2028-05 · Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
What this study did
NCT05922904 · M.D. Anderson Cancer Center
2023-12-14 – 2027-10-30 · Hodgkin Lymphoma
What this study did
NCT05404945 · University of Virginia
2022-07-26 – 2027-10-03 · Classical Hodgkin Lymphoma
What this study did
NCT04561206 · City of Hope Medical Center
2021-11-12 – 2027-10-02 · Relapsed Classic Hodgkin Lymphoma
What this study did
NCT03233347 · Academic and Community Cancer Research United
2017-10-13 – 2027-07-08 · Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma
What this study did
NCT03712202 · City of Hope Medical Center
2018-11-28 – 2027-05-21 · Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Mixed Cellularity Classic HL, Ann Arbor Stage II Nodular Sclerosis Classic HL
What this study did
NCT03007030 · M.D. Anderson Cancer Center
2017-04-05 – 2027-05-01 · CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma
What this study did
NCT06377566 · Memorial Sloan Kettering Cancer Center
2024-04-17 – 2027-04 · Hodgkin Lymphoma
What this study did
NCT03057795 · City of Hope Medical Center
2017-05-03 – 2027-02-25 · Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
What this study did
NCT05180097 · Canadian Cancer Trials Group
2022-11-01 – 2026-12-31 · Hodgkin Lymphoma
What this study did
NCT03517137 · European Organisation for Research and Treatment of Cancer - EORTC
2019-08-01 – 2026-11-16 · Advanced Hodgkin Lymphoma
What this study did
NCT04378647 · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
2020-06-01 – 2026-08-30 · Hodgkin Lymphoma, Adult
What this study did
NCT05243693 · National Cancer Center, Korea
2022-03 – 2026-03-31 · Relapsed/Refractory Classical Hodgkin Lymphoma
What this study did
NCT06201507 · Beijing Children's Hospital
2022-10-01 – 2025-12-31 · Hodgkin Lymphoma
What this study did
NCT03264131 · UNC Lineberger Comprehensive Cancer Center
2018-10-11 – 2025-12-15 · Lymphoma, Adult T-Cell Leukemia/Lymphoma, Lymphatic Diseases
What this study did
NCT02758717 · Academic and Community Cancer Research United
2016-05-13 – 2025-09-13 · Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage IIIA Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Classic Hodgkin Lymphoma
What this study did
NCT05149768 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2024-02-14 – 2025-07-23 · Diffuse Cutaneous Systemic Sclerosis
What this study did
NCT03409432 · John Reneau
2018-03-16 – 2025-07-16 · Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma
What this study did
NCT03652441 · University of Cologne
2019-11-13 – 2025-01-25 · Classical Hodgkin Lymphoma
What this study did
NCT05316246 · Shanghai Zhongshan Hospital
2022-06-01 – 2024-12-31 · NK/T Cell Lymphoma Nos
What this study did
NCT02588651 · Deepa Jagadeesh
2016-06-17 – 2024-10-14 · T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepato-splenic T-cell Lymphoma, Adult T-cell Leukemia/Lymphoma, Enteropathy Associated T-cell Lymphoma, NK T-cell Lymphoma
What this study did
NCT05006664 · Czech Lymphoma Study Group
2021-10 – 2024-10 · Lymphoma, T-Cell, Peripheral
What this study did
Phase 1/2 (25)
Diffuse Large B-Cell Lymphoma
NCT03356054 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2018-03-05 – 2027-02 · DLBCL
What this study did
NCT01994850 · Abramson Cancer Center at Penn Medicine
2013-11 – 2019-01 · CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30-Positive Gray Zone Lymphoma
What this study did
Peripheral T-Cell Lymphoma
NCT01805037 · Northwestern University
2013-03-05 – 2018-12-31 · Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Epstein-Barr Virus Infection, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
What this study did
Other / comorbidity
NCT02979522 · Takeda
2017-09-06 – 2029-09-24 · Hodgkin Disease
What this study did
NCT01896999 · National Cancer Institute (NCI)
2014-03-07 – 2027-06-30 · Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
What this study did
NCT02227199 · University of Washington
2014-10-10 – 2025-07-28 · Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
What this study did
NCT03187210 · Insel Gruppe AG, University Hospital Bern
2018-09-01 – 2025-04-30 · Lymphoma
What this study did
NCT01771107 · National Cancer Institute (NCI)
2013-03-08 – 2024-03-21 · AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage IIIA Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, HIV Infection
What this study did
NCT02729961 · University of Washington
2018-01-03 – 2023-07-01 · Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present, Systemic Anaplastic Large Cell Lymphoma
What this study did
NCT03222492 · National Institute of Allergy and Infectious Diseases (NIAID)
2017-09-20 – 2023-04-10 · Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
What this study did
NCT02098512 · New York Medical College
2014-03-01 – 2022-12-31 · Hodgkin Lymphoma
What this study did
NCT02467946 · Centre Antoine Lacassagne
2016-01-14 – 2022-04-06 · Clinical Efficacy, Safety
What this study did
NCT02581631 · Bristol-Myers Squibb
2016-02-11 – 2022-02-07 · Non-Hodgkin's Disease
What this study did
NCT02462538 · Arbeitsgemeinschaft medikamentoese Tumortherapie
2015-11-03 – 2021-11-03 · ALK+ Anaplastic Large Cell Lymphoma
What this study did
NCT02572167 · Seagen Inc.
2015-10-31 – 2021-10-21 · Hodgkin Lymphoma
What this study did
NCT01780662 · National Cancer Institute (NCI)
2013-01-31 – 2021-09-30 · Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Refractory Childhood Hodgkin Lymphoma
What this study did
NCT02686346 · The Lymphoma Academic Research Organisation
2016-03 – 2021-07-12 · Hodgkin Disease
What this study did
NCT02429375 · Memorial Sloan Kettering Cancer Center
2015-04-22 – 2021-02-17 · Hodgkin Lymphoma
What this study did
NCT02243436 · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
2014-11-11 – 2019-01-14 · CLASSICAL HODGKIN LYMPHOMA
What this study did
NCT01657331 · Columbia University
2012-07 – 2018-06 · Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma
What this study did
NCT01492088 · Millennium Pharmaceuticals, Inc.
2012-04-16 – 2018-04-12 · Relapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma
What this study did
NCT01874054 · Seagen Inc.
2013-06 – 2018-02-20 · Hodgkin Disease
What this study did
NCT02096042 · M.D. Anderson Cancer Center
2014-04 – 2016-08 · Leukemia
What this study did
NCT02408042 · Western Regional Medical Center
2015-04 – 2015-11 · Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma
What this study did
NCT01620229 · Fred Hutchinson Cancer Center
2013-06 – 2014-04 · Hematopoietic/Lymphoid Cancer
What this study did
Phase 1 (28)
Cutaneous T-Cell Lymphoma
NCT05414500 · University of Alabama at Birmingham
2023-05-01 – 2027-07-31 · Cutaneous T Cell Lymphoma, Mycosis Fungoides
What this study did
NCT02616965 · Fox Chase Cancer Center
2017-02-22 – 2024-01-31 · Cutaneous T-cell Lymphoma (CTCL)
What this study did
NCT03302728 · Peter MacCallum Cancer Centre, Australia
2018-08-30 – 2021-08-02 · Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Lymphoma
What this study did
NCT02822586 · Virginia Commonwealth University
2016-12-19 – 2019-04-29 · Mycosis Fungoides, Sézary Syndrome
What this study did
NCT03373305 · City of Hope Medical Center
2019-03 – 2019-04-26 · CD30-Positive Neoplastic Cells Present, Folliculotropic Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome
What this study did
Diffuse Large B-Cell Lymphoma
NCT04254107 · Seagen Inc.
2020-05-29 – 2023-12-01 · Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
What this study did
NCT02086604 · Washington University School of Medicine
2014-09-18 – 2022-01-12 · Lymphoma, Large B-Cell, Diffuse
What this study did
Peripheral T-Cell Lymphoma
NCT03719105 · New York Medical College
2019-03-01 – 2028-12-31 · NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
What this study did
NCT03205891 · M.D. Anderson Cancer Center
2018-03 – 2021-03 · Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma
What this study did
Other / comorbidity
NCT05244473 · Seagen Inc.
2022-12-31 – 2024-05-31 · Human Immunodeficiency Virus
What this study did
NCT03013933 · City of Hope Medical Center
2017-05-03 – 2022-05-24 · Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
What this study did
NCT02280993 · Marjolein Spiering
2014-05 – 2020-05 · Hodgkin Lymphoma, Refractory, Relapse
What this study did
NCT01830777 · Massachusetts General Hospital
2013-05 – 2019-05 · Acute Myelogenous Leukemia
What this study did
NCT02254239 · Mayo Clinic
2016-02-04 – 2018-12-12 · Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
What this study did
NCT02780011 · Eric Bernicker, MD
2015-12 – 2018-09 · CD30-positive Lymphoma, CD30-positive Solid Tumor
What this study did
NCT01900496 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2014-06 – 2017-07 · Lymphoma
What this study did
NCT01309789 · Seagen Inc.
2011-02 – 2017-02-28 · Lymphoma, Large-Cell, Anaplastic, Lymphoma, NK-cell, Lymphoma, T-cell
What this study did
NCT01596218 · Massachusetts General Hospital
2012-07 – 2016-12 · Graft vs. Host Disease
What this study did
NCT01940796 · Massachusetts General Hospital
2013-10 – 2016-12 · Graft-vs-Host Disease, GVHD
What this study did
NCT01700751 · Washington University School of Medicine
2013-02-25 – 2016-11-21 · Leukemia, Acute Myeloid, Leukemia, Lymphoblastic,Acute, Myelodysplastic Syndromes
What this study did
NCT02164006 · TG Therapeutics, Inc.
2014-06-11 – 2016-05 · Hodgkin's Lymphoma
What this study did
NCT01950364 · Millennium Pharmaceuticals, Inc.
2013-11 – 2015-06 · Hodgkin Lymphoma, Anaplastic Large-cell Lymphoma
What this study did
NCT01902160 · National Cancer Institute (NCI)
2013-09 – 2015-05 · Recurrent Adult Hodgkin Lymphoma
What this study did
NCT01060904 · Seagen Inc.
2010-01 – 2012-09 · Disease, Hodgkin
What this study did
NCT01026415 · Seagen Inc.
2009-12 – 2012-05 · Carcinomas, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin, Neoplasms
What this study did
NCT01026233 · Seagen Inc.
2010-01 – 2011-08 · Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
What this study did
NCT00649584 · Seagen Inc.
2008-03 – 2010-02 · Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
What this study did
NCT00430846 · Seagen Inc.
2006-11 – 2009-07 · Lymphoma, Non-Hodgkin, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic
What this study did
Phase 4 (5)
Cutaneous T-Cell Lymphoma
NCT05442554 · Takeda
2022-11-28 – 2024-08-09 · T-Cell Lymphoma
What this study did
Other / comorbidity
NCT06831370 · Takeda
2024-08-28 – 2028-03-31 · Hodgkin Lymphoma
What this study did
NCT06761911 · Xiuhua Sun
2024-12-31 – 2026-01-31 · Hodgkin Lymphoma (Category)
What this study did
NCT01909934 · Takeda
2014-01-23 – 2024-08-29 · Lymphoma
What this study did
NCT01990534 · Millennium Pharmaceuticals, Inc.
2014-03-14 – 2020-03-12 · Hodgkin Lymphoma
What this study did
Early phase / not applicable (6)
Peripheral T-Cell Lymphoma
NCT07074457 · The First Affiliated Hospital of Soochow University
2024-11-01 – 2028-11-01 · CD30+ Peripheral T-cell Lymphoma
What this study did
NCT01841021 · H. Lee Moffitt Cancer Center and Research Institute
2014-04 – 2016-06 · Peripheral T-Cell Lymphoma
What this study did
Other / comorbidity
NCT01868451 · Memorial Sloan Kettering Cancer Center
2013-05 – 2026-06-02 · Hodgkin Lymphoma
What this study did
NCT07171827 · Helwan University
2023-03-01 – 2025-02-01 · Anti-CD30, Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Frontline, Advanced Classical Hodgkin Lymphoma
What this study did
NCT01578967 · UNC Lineberger Comprehensive Cancer Center
2012-04 – 2020-12-11 · Hodgkin Lymphoma, Adult
What this study did
NCT01671813 · H. Lee Moffitt Cancer Center and Research Institute
2013-03 – 2013-07 · Lymphoma
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT02684292 · Merck Sharp & Dohme LLC
2016-05-23 – 2026-01-14 · Hodgkin Lymphoma
What this study did
Phase 2 (2)
Other / comorbidity
NCT06563778 · Chinese PLA General Hospital
2024-09-01 – 2028-09-01 · Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
What this study did
NCT06393361 · Chinese PLA General Hospital
2024-06-01 – 2027-06-01 · Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
What this study did

Competitive landscape

Other Anti-CD30 antibody-drug conjugate drugs

PF-08046044. Compare all 2 Anti-CD30 antibody-drug conjugate drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Cutaneous T-Cell Lymphoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Brentuximab Vedotin: this drugApprovedAntibody–drug conjugateAnti-CD30 antibody-drug conjugatePartial signal
NCT01578499: Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4) (Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months)): Brentuximab Vedotin 54.7 percentage of participants (95% CI 42.5 to 66.9) | Methotrexate or Bexarotene 12.5 percentage of participants (95% CI 4.4 to 20.6)
RomidepsinApprovedSmall moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
VorinostatApprovedSmall moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
LacutamabPhase 2Monoclonal antibodyKIR3DL2not yet gradedNo reviewed efficacy summary in this indication
PF-08046044
—(overall)
Antibody–drug conjugateAnti-CD30 antibody-drug conjugate
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(29 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Brentuximab Vedotin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Hodgkin LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT05180097 · CT.gov ↗
What to watch
2027 (13)
January 2027 (2)
Phase 2Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-01-01 · NCT03755804 · CT.gov ↗
What to watch
Phase 2Cutaneous T-Cell LymphomaRecruiting
Est. primary completion 2027-01-30 · NCT05357794 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Hodgkin LymphomaRecruiting
Est. primary completion 2027-04 · NCT06377566 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2CD30-Positive Neoplastic Cells Present, Malignant MesotheliomaActive not recruiting
Est. primary completion 2027-05-01 · NCT03007030 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1/2Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-06-30 · NCT01896999 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Cutaneous T-Cell LymphomaActive not recruiting
Est. primary completion 2027-07 · NCT03587844 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Large B-Cell LymphomaRecruiting
Est. primary completion 2027-08-03 · NCT04745949 · CT.gov ↗
What to watch
October 2027 (3)
Phase 2Relapsed Classic Hodgkin LymphomaRecruiting
Est. primary completion 2027-10-02 · NCT04561206 · CT.gov ↗
What to watch
Phase 2Classical Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-10-03 · NCT05404945 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-10-30 · NCT05922904 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaRecruiting
Est. primary completion 2027-11-30 · NCT05039073 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Recurrent Follicular Lymphoma, Refractory Follicular LymphomaActive not recruiting
Est. primary completion 2027-12 · NCT04587687 · CT.gov ↗
What to watch
Phase 1Peripheral T-Cell LymphomaRecruiting
Est. primary completion 2027-12-31 · NCT03719105 · CT.gov ↗
What to watch
2028 (7)
January 2028 (1)
Phase 2Cutaneous T-Cell LymphomaActive not recruiting
Est. primary completion 2028-01-31 · NCT01352520 · CT.gov ↗
What to watch
March 2028 (1)
Phase 4Hodgkin LymphomaRecruiting
Est. primary completion 2028-03-31 · NCT06831370 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2T-Cell LymphomaRecruiting
Est. primary completion 2028-04-30 · NCT05313243 · CT.gov ↗
What to watch
August 2028 (1)
Early phase / not applicablePeripheral T-Cell LymphomaRecruiting
Est. primary completion 2028-08-01 · NCT07074457 · CT.gov ↗
What to watch
December 2028 (3)
Phase 3Peripheral T-Cell LymphomaEnrolling by invitation
Est. primary completion 2028-12 · NCT07258680 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2028-12-30 · NCT06925555 · CT.gov ↗
What to watch
Phase 2Cutaneous T-Cell LymphomaNot yet recruiting
Est. primary completion 2028-12-30 · NCT07717580 · CT.gov ↗
What to watch
2029 (4)
March 2029 (1)
Phase 2/3Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaNot yet recruiting
Est. primary completion 2029-03-31 · NCT07572123 · CT.gov ↗
What to watch
July 2029 (1)
Phase 2Anaplastic Large Cell Lymphoma, ALK-PositiveRecruiting
Est. primary completion 2029-07-01 · NCT07013565 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Classic Hodgkin LymphomaRecruiting
Est. primary completion 2029-10-20 · NCT07275216 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2/3Classical Hodgkin Lymphoma, Child, Adolescent, Young Adult, Metabolic Response, Survival, Treatment, Brentuximab Vedotin, PET ScanRecruiting
Est. primary completion 2029-11-15 · NCT06563245 · CT.gov ↗
What to watch
2030 (2)
July 2030 (1)
Phase 2Hodgkin Lymphoma, Advanced Hodgkin LymphomaRecruiting
Est. primary completion 2030-07-15 · NCT07002216 · CT.gov ↗
What to watch
September 2030 (1)
Phase 3Hodgkin LymphomaRecruiting
Est. primary completion 2030-09 · NCT04685616 · CT.gov ↗
What to watch
2031 (1)
April 2031 (1)
Phase 3Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8Recruiting
Est. primary completion 2031-04-28 · NCT05675410 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
Phase 3Cutaneous T-Cell LymphomaNot yet recruiting
Est. primary completion 2032-11-01 · NCT07178457 · CT.gov ↗
What to watch

See the full readout calendar ↗